^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

2647 / 16 - RVU120, a selective CDK8/CDK19 inhibitor, demonstrates efficacy against hormone-independent breast cancer cells in vitro and in vivo

Published date:
03/09/2022
Excerpt:
These studies revealed that TNBC and ER-/PR-/HER2+ cells were highly sensitive to RVU120 and also to two other non-related CDK8/19 inhibitors, indicating a class effect.